PT  - JOURNAL ARTICLE
AU  - DAVID R. FOGELMAN
AU  - ROBERT A. WOLFF
AU  - SCOTT KOPETZ
AU  - MILIND JAVLE
AU  - CHARLES BRADLEY
AU  - ISABEL MOK
AU  - FERNANDO CABANILLAS
AU  - JAMES L. ABBRUZZESE
TI  - Evidence for the Efficacy of Iniparib, a PARP-1 Inhibitor, in BRCA2-associated Pancreatic Cancer
DP  - 2011 Apr 01
TA  - Anticancer Research
PG  - 1417--1420
VI  - 31
IP  - 4
4099  - http://ar.iiarjournals.org/content/31/4/1417.short
4100  - http://ar.iiarjournals.org/content/31/4/1417.full
SO  - Anticancer Res2011 Apr 01; 31
AB  - Pancreatic cancer is an aggressive, frequently fatal malignancy that strikes 37,000 patients annually in the U.S.A. It is poorly responsive to standard chemotherapies such as gemcitabine. Approximately 5-10% of pancreatic cancer occurs in the setting of a BRCA2 mutation. Breast and ovarian carcinomas that harbor BRCA2 mutations are susceptible to the effects of an emerging class of targeted agents, namely, poly(ADP-ribose) polymerase (PARP) inhibitors. This report describes the case of a patient with a germline BRCA2 mutation and an associated pancreatic cancer treated with iniparib (BSI-201), a PARP inhibitor, who demonstrated a complete pathologic response to this agent. This case highlights the potential benefit for PARP inhibition in BRCA2-related pancreatic cancer.